Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04518995 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
A Phase 3 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 706
- Enrollment target
NCT04518995 is a Phase 3 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 706 participants.
The verdict
NCT04518995, a Phase 3 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 706 participants
- Enrollment target
Study Summary
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
Interventions
- DRUG CTP-543
- DRUG CTP-543 matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2022-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04518995
The ClinicalTrials.gov registry entry for NCT04518995 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 706 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CTP-543 is the first listed.
NCT04518995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04518995 about?
NCT04518995 is a clinical study titled "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)". This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
What is the current status of trial NCT04518995?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 706 participants. The study started on 2020-11-23. Estimated completion is 2022-04-19.
What interventions are being tested in trial NCT04518995?
The interventions under investigation include: CTP-543 (DRUG), CTP-543 matching placebo (DRUG).
Who is sponsoring clinical trial NCT04518995?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.